Novartis, Teijin Pharma ink pact for preclinical candidate for proteinuric kidney diseases
Teijin Pharma will receive an upfront cash payment of USD 30 million from Novartis and is eligible to receive potential development and commercial milestone payments of up to USD 200 million.;
Advertisement
Tokyo: Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, has announced that it has entered into an exclusive global license agreement with Novartis to research, develop, manufacture and commercialize an investigational preclinical candidate for proteinuric kidney diseases.
The investigational small molecule candidate was discovered at the Teijin Institute for Bio-medical Research, Teijin Pharma’s drug development base in Tokyo. The candidate acts in a genetically validated pathway and is believed to impact the pathogenesis of multiple kidney diseases.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.